Novartis acquires Vedere Bio

By The Science Advisory Board staff writers

October 29, 2020 -- Novartis has acquired Vedere Bio in a deal that includes that company's lead preclinical intravitreally injected adeno-associated virus (AAV) gene therapy program, which focuses on pan-genotypic vision restoration in patients with photoreceptor-based vision loss.

Shareholders in Vedere Bio received $150 million upfront and will be eligible for up to $130 million in milestone payments. The company is based on technology directed at enhanced ocular gene therapy delivery out of the University of California, Berkeley and the University of Pennsylvania. The company has developed intravitreal capsids that enable optogenetics products and other ocular gene therapies.

Immediately prior to the acquisition, certain earlier-stage vision restoration and vision preservation assets leveraging the company's ocular gene therapy toolbox were spun out into a newly formed entity, called Vedere Bio II. The firm will operate as a wholly independent entity from Novartis and Vedere Bio. The new company will develop novel vision restoration and vision preservation medicines.

Sensorion, Novasep ink gene therapy agreement
Sensorion and Novasep have signed an agreement for the manufacturing of adeno-associated virus vectors covering a gene therapy program that targets OTOF,...
Bayer acquires Asklepios to advance gene therapies
Bayer has agreed to pay $2 billion to acquire Asklepios BioPharmaceutical, a U.S.-based biotechnology company specializing in gene therapies.
New methods could improve AAV quality for viral vector manufacturing
Developing well-characterized adeno-associated viral vectors (AAVs) is a significant obstacle for the biomanufacturing industry. A group of analytical...
Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter